Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma

6 Mar 2023

Abstract excerpt

Therapeutic targeting of CDK7 has proven beneficial in preclinical studies, yet the off-target effects of currently available CDK7 inhibitors make it difficult to pinpoint the exact mechanisms behind MM cell death mediated by CDK7 inhibition. Here, we show that CDK7 expression positively correlates with E2F and MYC transcriptional programs in cells from patients with multiple myeloma (MM); its selective targeting...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Multiple Myeloma Research and Treatments
Share to Protein Degradation and Inhibitors
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36877894
DOI: 10.1182/blood.2022018885

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myelomaPMID 36877894Read ↗

Metabolic Alterations in Multiple Myeloma: From Oncogenesis to Proteasome Inhibitor ResistanceSemantic proximity Read ↗

CDK7 Inhibitors in Cancer Therapy: The Sweet Smell of Success?Semantic proximity Read ↗

Cellular microRNA-127-3p suppresses oncogenic herpesvirus-induced transformation and tumorigenesis via down-regulation of SKP2Semantic proximity Read ↗

Identification of WNK1 as a therapeutic target to suppress IgH/MYC expression in multiple myelomaSemantic proximity Read ↗

Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myelomaSemantic proximity Read ↗

Cyclin dependent kinases in cancerSemantic proximity Read ↗

CDK7 in breast cancer: mechanisms of action and therapeutic potentialSemantic proximity Read ↗

PMM2 controls ERα levels and cell proliferation in ESR1 Y537S variant expressing breast cancer cellsSemantic proximity Read ↗

The pharmacodynamic and mechanistic foundation for the antineoplastic effects of GFH009, a potent and highly selective CDK9 inhibitor for the treatment of hematologic malignanciesSemantic proximity Read ↗

Discovery of KB-0742, a Potent, Selective, Orally Bioavailable Small Molecule Inhibitor of CDK9 for MYC-Dependent CancersSemantic proximity Read ↗

PMM2 controls ERα levels and cell proliferation in ESR1 Y537S variant expressing breast cancer cells.Semantic proximity Read ↗

The EGFL7-ITGB3-KLF2 axis enhances survival of multiple myeloma in preclinical modelsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.